These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31529107)

  • 1. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
    de Vries R; Muller M; van der Noort V; Theelen WSME; Schouten RD; Hummelink K; Muller SH; Wolf-Lansdorf M; Dagelet JWF; Monkhorst K; Maitland-van der Zee AH; Baas P; Sterk PJ; van den Heuvel MM
    Ann Oncol; 2019 Oct; 30(10):1660-1666. PubMed ID: 31529107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer.
    Buma AIG; Muller M; de Vries R; Sterk PJ; van der Noort V; Wolf-Lansdorf M; Farzan N; Baas P; van den Heuvel MM
    Lung Cancer; 2021 Oct; 160():36-43. PubMed ID: 34399166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Detection of Early Lung Cancer in Patients With COPD in Regular Care by Electronic Nose Analysis of Exhaled Breath.
    de Vries R; Farzan N; Fabius T; De Jongh FHC; Jak PMC; Haarman EG; Snoey E; In 't Veen JCCM; Dagelet YWF; Maitland-Van Der Zee AH; Lucas A; Van Den Heuvel MM; Wolf-Lansdorf M; Muller M; Baas P; Sterk PJ
    Chest; 2023 Nov; 164(5):1315-1324. PubMed ID: 37209772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
    Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
    Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
    Disselhorst MJ; de Vries R; Quispel-Janssen J; Wolf-Lansdorf M; Sterk PJ; Baas P
    Eur J Cancer; 2021 Jul; 152():60-67. PubMed ID: 34087572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
    Tambo Y; Sone T; Shibata K; Nishi K; Shirasaki H; Yoneda T; Araya T; Kase K; Nishikawa S; Kimura H; Kasahara K
    Clin Lung Cancer; 2020 Sep; 21(5):e366-e379. PubMed ID: 32199806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer.
    Muller M; Hoogendoorn R; Moritz RJG; van der Noort V; Lanfermeijer M; Korse CM; van den Broek D; Ten Hoeve JJ; Baas P; van Rossum HH; van den Heuvel MM
    Tumour Biol; 2021; 43(1):115-127. PubMed ID: 34219680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of electronic nose technology with spirometry: validation of a new approach for exhaled breath analysis.
    de Vries R; Brinkman P; van der Schee MP; Fens N; Dijkers E; Bootsma SK; de Jongh FH; Sterk PJ
    J Breath Res; 2015 Oct; 9(4):046001. PubMed ID: 26469298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology.
    van der Sar IG; Wijsenbeek MS; Braunstahl GJ; Loekabino JO; Dingemans AC; In 't Veen JCCM; Moor CC
    Respir Res; 2023 Nov; 24(1):271. PubMed ID: 37932795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
    Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
    Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer.
    Nardi-Agmon I; Abud-Hawa M; Liran O; Gai-Mor N; Ilouze M; Onn A; Bar J; Shlomi D; Haick H; Peled N
    J Thorac Oncol; 2016 Jun; 11(6):827-37. PubMed ID: 26968885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
    Di Noia V; D'Argento E; Pilotto S; Vita E; Ferrara MG; Damiano P; Ribelli M; Cannella A; Virtuoso A; Fattorossi A; Ceresoli GL; Milella M; Beretta GD; Tortora G; Bria E
    Cancer Immunol Immunother; 2021 Jun; 70(6):1583-1592. PubMed ID: 33231726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosing Non-Small Cell Lung Cancer by Exhaled Breath Profiling Using an Electronic Nose: A Multicenter Validation Study.
    Kort S; Brusse-Keizer M; Schouwink H; Citgez E; de Jongh FH; van Putten JWG; van den Borne B; Kastelijn EA; Stolz D; Schuurbiers M; van den Heuvel MM; van Geffen WH; van der Palen J
    Chest; 2023 Mar; 163(3):697-706. PubMed ID: 36243060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
    Miyawaki T; Kenmotsu H; Mori K; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
    Clin Lung Cancer; 2020 Sep; 21(5):e405-e414. PubMed ID: 32205040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.